

FDA Approval of HIV Medicines

1981: First AIDS cases are reported in the United States.

1985-89	1990-94	1995-99	2000-04	2005-09	2010-14	2015-19	2020-24
1987 Zidovudine (NRTI)	1991 Didanosine* (NRTI) 1992 Zalcitabine* (NRTI) 1994 Stavudine* (NRTI)	1995 Lamivudine (NRTI) Saquinavir Mesylate* (PI) 1996 Indinavir* (PI) Nevirapine (NNRTI) Ritonavir (PI) 1997 Combivir† (FDC) Delavirdine* (NNRTI) Nelfinavir* (PI) Saquinavir* (PI) 1998 Abacavir (NRTI) Efavirenz (NNRTI) 1999 Amprenavir* (PI)	2000 Didanosine EC* (NRTI) Kaletra (FDC) Trizivir* (FDC) 2001 Tenofovir DF (NRTI) 2002 Stavudine XR* (NRTI) 2003 Atazanavir (PI) Emtricitabine (NRTI) Enfuvirtide* (FI) Fosamprenavir* (PI) 2004 Epzicom† (FDC) Truvada (FDC)	2005 Tipranavir* (PI) 2006 Atripla† (FDC) Darunavir (PI) 2007 Maraviroc (CA) Raltegravir (INSTI) 2008 Etravirine (NNRTI)	2011 Complera (FDC) Nevirapine XR (NNRTI) Rilpivirine (NNRTI) 2012 Stribild (FDC) Truvada (PrEP) 2013 Dolutegravir (INSTI) 2014 Cobicistat (PE) Elvitegravir* (INSTI) Triumeq (FDC)	2015 Evotaz (FDC) Genvoya (FDC) Prezcobix (FDC) 2016 Descovy (FDC) Odefsey (FDC) 2017 Juluca (FDC) Raltegravir HD (INSTI) 2018 Biktarvy (FDC) Cimduo (FDC) Delstrigo (FDC) Doravirine (NNRTI) Ibalizumab-uiyk (PAI) Symfi (FDC) Symfi Lo† (FDC) Symtuza (FDC) Temixys* (FDC) 2019 Dovato (FDC) Descovy (PrEP)	2020 Fostemsavir* (AI) Tivicay PD (INSTI) 2021 Cabenuva (FDC) Cabotegravir (INSTI) Cabotegravir (PrEP) 2022 Triumeq PD (FDC) Lenacapavir (CI) 2024 Rilpivirine PED (NNRTI) 2025 Lenacapavir (PrEP)

Drug Class Abbreviations:
AI: Attachment Inhibitor; CA: CCR5 Antagonist; CI: Capsid Inhibitors; FDC: Fixed-Dose Combination; FI: Fusion Inhibitor;
INSTI: Integrase Inhibitor; NNRTI: Non-Nucleoside Reverse Transcriptase Inhibitor; NRTI: Nucleoside Reverse Transcriptase Inhibitor; PE: Pharmacokinetic Enhancer; PI: Protease Inhibitor; PAI: Post-Attachment Inhibitor; PrEP: Pre-exposure prophylaxis

Note: Approvals are for HIV treatment, unless otherwise indicated.
*Drugs in gray are no longer available and/or are no longer recommended for use in the United States by the HHS HIV/AIDS medical practice guidelines. These drugs may still be used in fixed-dose combination formulations.
†Fixed-dose combination brand products that are available as generic only.